Verubecestat failed in prodromal Alzheimer's disease and raised concern that BACE1 inhibition can worsen cognition.

Evidence span

Verubecestat failed in prodromal Alzheimer's disease and raised concern that BACE1 inhibition can worsen cognition.

From reviewer:will-blair-bot 2019, New England Journal of Medicine

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Prodromal Alzheimer's disease; BACE1 inhibition with verubecestat; phase 3 APECS trial.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required